U.S. Markets closed

Merck & Co., Inc. (MRK.BA)

Buenos Aires - Buenos Aires Delayed Price. Currency in ARS
Add to watchlist
104.250.00 (0.00%)
At close: 4:07PM ART
Full screen
Previous Close104.25
Bid80.00 x
Ask0.00 x
Day's Range104.25 - 104.25
52 Week Range97.55 - 105.00
Avg. Volume593
Market Cap2.66T
PE Ratio (TTM)66.44
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Reuters3 hours ago

    Merck immunotherapy fails to improve survival in head and neck cancer

    Merck & Co said on Monday that its Keytruda immunotherapy failed to extend survival in previously treated patients with advanced head and neck cancer more than the standard combination therapy in a late-stage trial. The drug, which blocks a mechanism tumors use to hide from the immune system allowing it to recognize and attack the cancer, won accelerated U.S. approval last August for these patients based on its ability to shrink tumors. As a condition of the accelerated approval, Merck was required to conduct a trial to demonstrate superiority over standard treatment and verify the clinical benefit of Keytruda in this patient population.

  • Benzinga6 hours ago

    Ahead Of Earnings: Why You Should Be Buying Merck And Selling Bristol-Myers

    Pharmaceutical giants Bristol-Myers Squibb Co (NYSE: BMY ) and Merck & Co., Inc. (NYSE: MRK ) both release their second quarter earnings reports this week. According to BMO Capital, investors should be ...

  • Merck, Samsung Accelerate a Biosimilar Price War
    Bloomberg6 hours ago

    Merck, Samsung Accelerate a Biosimilar Price War

    The days of high-priced knockoffs of biologic drugs are ending quickly.